Pfizer announced on Friday that a Phase 2 clinical trial of its immunotherapy Elrexfio extended the life expectancy of patients with relapsed or refractory multiple myeloma by more than two years.

According to the company, the 123 participants in the trial enjoyed a median overall survival of 24.6 months, while progression-free survival reached 17.2 months.

Last year, the FDA granted Elrexfio marketing authorization for the treatment of relapsed or refractory multiple myeloma (RRMM) in adults having received at least three prior lines of treatment.

The European Commission followed suit, granting conditional authorization for the product in the same indication.

Multiple myeloma, commonly known as myeloma, is an aggressive type of blood cancer which is currently incurable, affecting plasma cells produced by the bone marrow.

Copyright (c) 2024 CercleFinance.com. All rights reserved.